Pharma News

Merck China has announced significant organizational changes, including the dissolution of its Diabetes Business Unit (DBU) and the establishment of a new Entrepreneurial Business Unit (EBU).

Novartis has made significant strides in the chronic spontaneous urticaria (CSU) market, announcing a priority review application for its BTK inhibitor Remibrutinib and a $830 million deal to acquire Kyorin's clinical-stage MRGPRX2 antagonist.

On March 12, Roche made headlines by announcing a groundbreaking partnership with Danish pharmaceutical company Zealand Pharma to develop and commercialize Petrelintide, an amylin analog.

On March 9, Synlogic announced that its self-developed drug TY-9591 has successfully outperformed AstraZeneca's renowned lung cancer treatment, Osimertinib, in a pivotal Phase II clinical trial.

Dupilumab has emerged as the "king of autoimmune drugs" with a staggering $14.179 billion in sales. Despite its approval for seven indications, its dominance is primarily rooted in atopic dermatitis (AD).

A spokesperson from the Ministry of Public Security emphasized that China maintains one of the strictest drug control policies in the world.

Pfizer announced the appointment of Dr. James List as its new Chief Medical Officer for Internal Medicine. In this pivotal role, Dr. List will oversee Pfizer's internal medicine portfolio, managing everything from early drug discovery to late-stage develo

Bayer's CEO, Bill Anderson, has seen his total compensation drop to approximately €8.84 million ($9.6 million) for 2024, marking a 21% decrease compared to the previous year.

Bio-Thera Biopharmaceutical Co., Ltd. announced that it has received a resignation letter from Liu Cuihua, a non-independent director and vice president, who has stepped down for personal reasons.

On March 10, 2025, it was reported that Eli Lilly's CEO, David Ricks, has experienced a 10% increase in his total compensation for 2024, bringing his earnings to an impressive $29.2 million.

The Canadian government has announced a $5 million investment in Konscious Foods, a plant-based seafood company based in British Columbia.

On February 14, 2025, Japan's Consumer Affairs Agency announced the successful safety review of a transgenic polyphenol oxidase developed by Novozymes, a Danish biotechnology company.

Novo Nordisk has experienced another setback as it released disappointing data from its late-stage trial for CagriSema, a new obesity treatment. On March 11, 2025, the company reported that the results from the REDEFINE 2 trial did not meet market expecta

The Indian pharmaceutical sector, particularly Contract Development and Manufacturing Organizations (CDMOs), is poised to withstand the impact of proposed 10-25% tariffs from the United States, according to a recent report by B&K Securities.

Novo Nordisk's latest trial results for its next-generation diabetes drug, CagriSema, have revealed a 15.7% weight loss in overweight or obese patients with type 2 diabetes after 68 weeks of treatment.

On March 11, 2025, India and Armenia strengthened their bilateral ties by signing a significant Memorandum of Understanding (MoU) aimed at enhancing cooperation in the regulation of medical products.

In a strategic move to enhance its onco-dermatology offerings, Sun Pharmaceutical Industries has announced its acquisition of Checkpoint Therapeutics for an impressive $355 million.

In the ongoing global patent disputes surrounding COVID-19 vaccines, Pfizer and BioNTech scored a significant victory this week against rival Moderna as two crucial decisions were rendered in the United States and Germany.

Merck & Co. and Halozyme are engaged in a fierce patent dispute regarding the injectable formulation of Keytruda, Merck's leading cancer drug.

ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company, has announced plans to significantly boost its investment in U.S. operations, with over $100 million already invested since 2015.